Danaher Corporation $DHR Holdings Reduced by NewEdge Advisors LLC

NewEdge Advisors LLC lessened its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 79.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 54,764 shares of the conglomerate's stock after selling 215,283 shares during the period. NewEdge Advisors LLC's holdings in Danaher were worth $10,431,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in shares of Danaher in the 2nd quarter worth approximately $3,807,000. Northwestern Mutual Wealth Management Co. grew its position in Danaher by 303.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate's stock worth $56,777,000 after buying an additional 186,584 shares during the last quarter. Puzo Michael J bought a new position in shares of Danaher in the second quarter valued at $8,624,000. First Nebraska Trust Co bought a new position in shares of Danaher in the second quarter valued at $14,106,000. Finally, Madison Asset Management LLC acquired a new stake in shares of Danaher during the 2nd quarter valued at $85,451,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DHR has been the subject of several research reports. UBS Group assumed coverage on Danaher in a research note on Wednesday. They set a "buy" rating and a $250.00 price objective for the company. Guggenheim cut their target price on Danaher from $235.00 to $200.00 and set a "buy" rating on the stock in a research report on Wednesday, July 22nd. HSBC reduced their target price on Danaher from $270.00 to $230.00 and set a "buy" rating for the company in a report on Wednesday, June 3rd. Stifel Nicolaus dropped their price target on Danaher from $260.00 to $220.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. Finally, TD Cowen dropped their price target on Danaher from $240.00 to $236.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $228.91.

Danaher Price Performance

NYSE DHR opened at $200.30 on Friday. The stock has a market capitalization of $140.81 billion, a PE ratio of 35.58, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a 50 day moving average price of $202.65 and a two-hundred day moving average price of $192.08. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business's quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.77 earnings per share. As a group, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company's portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.